King Wong has extensive experience in preparing and/or prosecuting patent applications, including re-examinations and reissues, dealing with pharmaceuticals, chemicals, neutraceuticals, biotechnology, diagnostics, biologics such as vaccines, cosmetics, automotive parts, and fuel cells both in the United States and abroad, as well as dealing with designs and new varieties of plants in the United States. He has managed worldwide patent application portfolios for clients. He has provided freedom-to-operate, invalidity and patentability opinions related to U.S. patents in the areas of pharmaceuticals, chemicals and biotechnology. He has also advised clients, ranging from Fortune 500 companies to start-ups, in various issues dealing with patent law.
Prior to practicing law, Dr. Wong was a patent examiner at the U.S. Patent and Trademark Office (USPTO) in the organic chemistry group. His scientific experience includes performing laboratory research in pharmacology and toxicology and providing toxicological support for NASA in the Space Shuttle and Space Station programs. Dr. Wong has co-authored over 20 articles published in biomedical journals. He was also a co-author of an article, entitled "Poisons and Poisoning," in the Encyclopedia Britannica. In addition, he was a faculty member of the Graduate School of Public Health, University of Pittsburgh, where he reached the rank of Assistant Professor.
- Teva Pharmaceuticals, one of the world’s largest pharmaceutical companies, in prosecuting its patent applications before the USPTO.
- Sanovel, a Turkish pharmaceutical company, in prosecuting its patent applications before the USPTO.
- Response Genetics, Inc., an innovative life sciences company, in prosecuting its patent applications in the United States and a number of foreign countries, and also in assisting it in the completion of filings at the Security Exchange Commission, and providing relevant information for its due diligence, audits and potential investors.
- Dr. Dennis Gross Skincare, a firm involved in the research and development of skincare products, in providing consultation and strategy planning in patent prosecution and litigation related to its products and technologies.
- “Extension of USPTO Pilot on Information Disclosure after Issue Fee Payment,” Law360, October 1, 2013.
- “Update on USPTO’s After Final Consideration Pilot 2.0,” Law360, September 25, 2013.